Zhejiang Shengda Pharm (603079) - Net Assets
Based on the latest financial reports, Zhejiang Shengda Pharm (603079) has net assets worth CN¥1.63 Billion CNY (≈ $238.60 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.19 Billion ≈ $320.83 Million USD) and total liabilities (CN¥561.97 Million ≈ $82.23 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Zhejiang Shengda Pharm's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.63 Billion |
| % of Total Assets | 74.37% |
| Annual Growth Rate | 18.09% |
| 5-Year Change | 20.78% |
| 10-Year Change | 266.98% |
| Growth Volatility | 23.66 |
Zhejiang Shengda Pharm - Net Assets Trend (2012–2025)
This chart illustrates how Zhejiang Shengda Pharm's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Zhejiang Shengda Pharm to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang Shengda Pharm (2012–2025)
The table below shows the annual net assets of Zhejiang Shengda Pharm from 2012 to 2025. For live valuation and market cap data, see 603079 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.61 Billion ≈ $236.30 Million |
+25.77% |
| 2024-12-31 | CN¥1.28 Billion ≈ $187.89 Million |
+1.10% |
| 2023-12-31 | CN¥1.27 Billion ≈ $185.84 Million |
-5.47% |
| 2022-12-31 | CN¥1.34 Billion ≈ $196.59 Million |
+0.48% |
| 2021-12-31 | CN¥1.34 Billion ≈ $195.64 Million |
+0.90% |
| 2020-12-31 | CN¥1.33 Billion ≈ $193.90 Million |
+45.34% |
| 2019-12-31 | CN¥911.71 Million ≈ $133.41 Million |
+10.05% |
| 2018-12-31 | CN¥828.42 Million ≈ $121.22 Million |
+7.77% |
| 2017-12-31 | CN¥768.71 Million ≈ $112.49 Million |
+74.70% |
| 2016-12-31 | CN¥440.02 Million ≈ $64.39 Million |
+0.21% |
| 2015-12-31 | CN¥439.09 Million ≈ $64.25 Million |
+35.16% |
| 2014-12-31 | CN¥324.87 Million ≈ $47.54 Million |
+15.58% |
| 2013-12-31 | CN¥281.09 Million ≈ $41.13 Million |
+51.13% |
| 2012-12-31 | CN¥185.99 Million ≈ $27.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Shengda Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 675.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥444.88 Million | 28.08% |
| Other Components | CN¥1.14 Billion | 71.92% |
| Total Equity | CN¥1.58 Billion | 100.00% |
Zhejiang Shengda Pharm Competitors by Market Cap
The table below lists competitors of Zhejiang Shengda Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Morguard Real Estate Investment Trust
TO:MRT-UN
|
$327.02 Million |
|
Jiin Yeeh Ding Enterprise Co Ltd
TWO:8390
|
$327.04 Million |
|
Lihe Technology
SHE:300800
|
$327.05 Million |
|
Kung Long Batteries Industrial Co Ltd
TW:1537
|
$327.05 Million |
|
Sungwoo Hitech Co. Ltd
KQ:015750
|
$326.88 Million |
|
Silence Therapeutics PLC
NASDAQ:SLN
|
$326.86 Million |
|
Bell Financial Group Ltd
AU:BFG
|
$326.80 Million |
|
Antibiotice Ia
RO:ATB
|
$326.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Shengda Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,260,831,652 to 1,584,548,889, a change of 323,717,237 (25.7%).
- Net income of 62,155,712 contributed positively to equity growth.
- Dividend payments of 7,813,280 reduced retained earnings.
- Other factors increased equity by 269,374,805.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥62.16 Million | +3.92% |
| Dividends Paid | CN¥7.81 Million | -0.49% |
| Other Changes | CN¥269.37 Million | +17.0% |
| Total Change | CN¥- | 25.67% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Shengda Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.47x to 1.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥3.41 | CN¥11.82 | x |
| 2013-12-31 | CN¥2.55 | CN¥11.82 | x |
| 2014-12-31 | CN¥2.76 | CN¥11.82 | x |
| 2015-12-31 | CN¥3.75 | CN¥11.82 | x |
| 2016-12-31 | CN¥3.76 | CN¥11.82 | x |
| 2017-12-31 | CN¥5.90 | CN¥11.82 | x |
| 2018-12-31 | CN¥5.07 | CN¥11.82 | x |
| 2019-12-31 | CN¥5.64 | CN¥11.82 | x |
| 2020-12-31 | CN¥7.73 | CN¥11.82 | x |
| 2021-12-31 | CN¥7.67 | CN¥11.82 | x |
| 2022-12-31 | CN¥7.59 | CN¥11.82 | x |
| 2023-12-31 | CN¥7.43 | CN¥11.82 | x |
| 2024-12-31 | CN¥7.28 | CN¥11.82 | x |
| 2025-12-31 | CN¥8.38 | CN¥11.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Shengda Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.36%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.39x
- Recent ROE (3.92%) is below the historical average (10.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 33.99% | 11.65% | 0.89x | 3.29x | CN¥36.96 Million |
| 2013 | 19.42% | 13.69% | 0.79x | 1.80x | CN¥26.48 Million |
| 2014 | 13.48% | 11.50% | 0.69x | 1.69x | CN¥11.30 Million |
| 2015 | 19.75% | 16.16% | 0.86x | 1.42x | CN¥42.79 Million |
| 2016 | 13.85% | 12.64% | 0.65x | 1.68x | CN¥16.93 Million |
| 2017 | 9.45% | 14.28% | 0.52x | 1.28x | CN¥-4.26 Million |
| 2018 | 5.63% | 9.04% | 0.39x | 1.58x | CN¥-34.58 Million |
| 2019 | 5.32% | 9.06% | 0.34x | 1.73x | CN¥-41.35 Million |
| 2020 | 15.13% | 22.76% | 0.51x | 1.30x | CN¥66.97 Million |
| 2021 | 5.74% | 9.59% | 0.45x | 1.34x | CN¥-56.29 Million |
| 2022 | 2.37% | 4.27% | 0.45x | 1.25x | CN¥-101.32 Million |
| 2023 | -4.31% | -7.43% | 0.42x | 1.37x | CN¥-179.53 Million |
| 2024 | 2.33% | 3.56% | 0.46x | 1.42x | CN¥-96.66 Million |
| 2025 | 3.92% | 7.36% | 0.38x | 1.39x | CN¥-96.30 Million |
Industry Comparison
This section compares Zhejiang Shengda Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,382,925,767
- Average return on equity (ROE) among peers: 7.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Shengda Pharm (603079) | CN¥1.63 Billion | 33.99% | 0.34x | $326.95 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.78 Billion | 1.33% | 4.40x | $527.47 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $775.01 Million | 2.45% | 0.87x | $355.63 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.87 Billion | 20.71% | 0.25x | $4.12 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.13 Billion | 5.48% | 0.64x | $2.54 Billion |
| Wedge Industrial Co Ltd (000534) | $549.14 Million | 1.31% | 0.01x | $2.15 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $39.91 Billion | 10.26% | 0.35x | $12.31 Billion |
| Hainan Haiyao Co Ltd (000566) | $445.29 Million | 14.73% | 0.90x | $871.39 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $271.26 Million | 1.07% | 1.01x | $306.62 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $910.49 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $23.53 Billion | 7.26% | 0.16x | $3.21 Billion |
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.